Synthesis, cytotoxicity of new 4-arylidene curcumin analogues and their multi-functions in inhibition of both NF-κB and Akt signalling

European Journal of Medicinal Chemistry

Volumn 55, Issue , 2012, Pages 346-357

  Zuo, Yinglin ^a   Huang, Jianing ^a   Zhou, Binhua ^a   Wang, Shuni ^a   Shao, Weiyan ^a   Zhu, Cuige ^a   Lin, Li ^a   Wen, Gesi ^a   Wang, Hongyang ^a   Du, Jun ^a   Bu, Xianzhang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

4 Arylidene curcumin analogues; Akt inhibition; Cytotoxicity; Docking; NF B inhibition

Indexed keywords

1,7 BIS(2,3 DIMETHOXYPHENYL) 4 (2,3,4 TRIMETHOXYBENZYLIDENE)HEPTA 1,6 DIENE 3,5 DIONE; 1,7 BIS(2,3 DIMETHOXYPHENYL) 4 (2,4,6 TRIMETHOXYBENZYLIDENE)HEPTA 1,6 DIENE 3,5 DIONE; 1,7 BIS(2,3 DIMETHOXYPHENYL) 4 (3 FLUORO 4 HYDROXYBENZYLIDENE)HEPTA 1,6 DIENE 3,5 DIONE; 1,7 BIS(2,3 DIMETHOXYPHENYL) 4 (3 HYDROXY 4 METHOXYBENZYLIDENE)HEPTA 1,6 DIENE 3,5 DIONE; 1,7 BIS(2,3 DIMETHOXYPHENYL) 4 (3,4,5 TRIMETHOXYBENZYLIDENE)HEPTA 1,6 DIENE 3,5 DIONE; 1,7 BIS(2,3 DIMETHOXYPHENYL) 4 (4 FLUOROBENZYLIDENE)HEPTA 1,6 DIENE 3,5 DIONE; 1,7 BIS(2,3 DIMETHOXYPHENYL) 4 (4 HYDROXY 3 METHOXYBENZYLIDENE)HEPTA 1,6 DIENE 3,5 DIONE; 1,7 BIS(2,3 DIMETHOXYPHENYL) 4 (4 HYDROXY 3,5 DIMETHOXYBENZYLIDENE)HEPTA 1,6 DIENE 3,5 DIONE; 1,7 BIS(2,3 DIMETHOXYPHENYL) 5 HYDROXYHEPTA 1,4,6 TRIEN 3 ONE; 1,7 BIS(2,4 DIMETHOXYPHENYL) 4 (3 FLUORO 4 HYDROXYBENZYLIDENE)HEPTA 1,6 DIENE 3,5 DIONE; 1,7 BIS(2,4 DIMETHOXYPHENYL) 4 (4 HYDROXY 3 METHOXYBENZYLIDENE)HEPTA 1,6 DIENE 3,5 DIONE; 1,7 BIS(2,4 DIMETHOXYPHENYL) 5 HYDROXYHEPTA 1,4,6 TRIEN 3 ONE; 1,7 BIS(2,5 DIMETHOXYPHENYL) 4 (3 FLUORO 4 HYDROXYBENZYLIDINE)HEPTA 1,6 DIENE 3,5 DIONE; 1,7 BIS(2,5 DIMETHOXYPHENYL) 4 (3 HYDROXY 4 METHOXYBENZYLIDENE)HEPTA 1,6 DIENE 3,5 DIONE; 1,7 BIS(2,5 DIMETHOXYPHENYL) 4 (4 HYDROXY 3,5 DIMETHOXYBENZYLIDENE)HEPTA 1,6 DIENE 3,5 DIONE; 1,7 BIS(2,5 DIMETHOXYPHENYL) 5 HYDROXYHEPTA 1,4,6 TRIEN 3 ONE; 4 (2,3 DIMETHOXYBENZYLIDENE) 1,7 BIS(2,3 DIMETHOXYPHENYL)HEPTA 1,6 DIENE 3,5 DIONE; 4 (3 BROMO 4 HYDROXY 5 METHOXYBENZYLIDENE 1,7 BIS(2,3 DIMETHOXYPHENYL)HEPTA 1,6 DIENE 3,5 DIONE; 4 (3 BROMO 4 HYDROXY 5 METHOXYBENZYLIDENE 1,7 BIS(2,4 DIMETHOXYPHENYL)HEPTA 1,6 DIENE 3,5 DIONE; 4 (3 BROMO 4 HYDROXY 5 METHOXYBENZYLIDENE 1,7 BIS(2,5 DIMETHOXYPHENYL)HEPTA 1,6 DIENE 3,5 DIONE; 4 (3,4 DIMETHOXYBENZYLIDENE) 1,7 BIS(2,3 DIMETHOXYPHENYL)HEPTA 1,6 DIENE 3,5 DIONE; 4 (3,4 DIMETHOXYBENZYLIDENE) 1,7 BIS(2,5 DIMETHOXYPHENYL)HEPTA 1,6 DIENE 3,5 DIONE; 4 ARYLIDENE CURCUMIN DERIVATIVE; 5 HYDROXY 1,7 BIS(2,4,6 TRIMETHOXYPHENYL)HEPTA 1,4,6 TRIEN 3 ONE; CURCUMIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASSAY; CANCER CELL CULTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY TECHNIQUES, SYNTHETIC; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MOLECULAR DOCKING SIMULATION; NF-KAPPA B; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84865800786     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.07.039     Document Type: Article

References (46)

1. S. Ghosh, M. May, and E. Kopp NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses Annu. Rev. Immunol. 16 1998 225 260
2. S. Shukla, G. MacLennan, P. Fu, J. Patel, S. Marengo, M. Resnick, and S. Gupta Nuclear factor-nB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression Neoplasia 6 2004 390 400
3. H. Ni, M. Ergin, Q. Huang, J. Qin, H. Amin, R. Martinez, S. Saeed, K. Barton, and S. Alkan Analysis of expression of nuclear factor [κ] B (NF-[κ] B) in multiple myeloma: downregulation of NF-[κ] B induces apoptosis Br. J. Haematol. 115 2001 279
4. M. Guzman, S. Neering, D. Upchurch, B. Grimes, D. Howard, D. Rizzieri, S. Luger, and C. Jordan Nuclear factor-{κ} B is constitutively activated in primitive human acute myelogenous leukemia cells Blood 98 2001 2301
5. X. Tang, S. Shishodia, C. Behrens, W. Hong, and I. Wistuba Nuclear factor-κB (NF-κB) is frequently expressed in lung cancer and preneoplastic lesions Cancer 107 2006 2637 2646
6. S. Huang, A. DeGuzman, C. Bucana, and I. Fidler Nuclear factor-κB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice 1 Clin. Cancer Res. 6 2000 2573 2581
7. A. Farina, A. Tacconelli, A. Vacca, M. Maroder, A. Gulino, and A. Mackay Transcriptional up-regulation of matrix metalloproteinase-9 expression during spontaneous epithelial to neuroblast phenotype conversion by SK-N-SH neuroblastoma cells, involved in enhanced invasivity, depends upon GT-Box and nuclear factor κB elements 1 Cell. Growth Differ. 10 1999 353 367
8. C. Wang, M. Mayo, R. Korneluk, D. Goeddel, and A. Baldwin Jr. NF-B antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation Science 281 1998 1680
9. M. Karin Nuclear factor-κB in cancer development and progression Nature 441 2006 431 436
10. L. Qiao, H. Zhang, J. Yu, R. Francisco, P. Dent, M. Ebert, C. Rocken, and G. Farrell Constitutive activation of NF-κB in human hepatocellular carcinoma: evidence of a cytoprotective role Hum. Gene Ther. 17 2006 280 290
11. M. Notarbartolo, P. Poma, D. Perri, L. Dusonchet, M. Cervello, and N. D'Alessandro Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression Cancer Lett. 224 2005 53 65
12. X. Wang, W. Ju, J. Renouard, J. Aden, S.A. Minsky, and Y. Lin 17-Allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappa B pathway Cancer Res. 66 2006 1089 1095
13. C.W. Lindsley, S.F. Barnett, M.E. Layton, and M.T. Bilodeau The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors Curr. Cancer Drug Targets 8 2008 7 18
14. A. Dey, V. Tergaonkar, and D.P. Lane Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways Nat. Rev. Drug Disc. 7 2008 1031 1040
15. R.J. Vlietstra, D.C.J.G. van Alewijk, K.G.L. Hermans, G.J. van Steenbrugge, and J. Trapman Frequent inactivation of PTEN in prostate cancer cell lines and xenografts Cancer Res. 58 1998 2720 2723
16. Z.Q. Yuan, M. Sun, R.I. Feldman, G. Wang, X. Ma, C. Jiang, D. Coppola, S.V. Nicosia, and J.Q. Cheng Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer Oncogene 19 2000 2324
17. E. Tokunaga, Y. Kimura, E. Oki, N. Ueda, M. Futatsugi, K. Mashino, M. Yamamoto, M. Ikebe, Y. Kakeji, H. Baba, and Y. Maehara Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients Int. J. Cancer 118 2006 284 289
18. E. Tokunaga, A. Kataoka, Y. Kimura, E. Oki, K. Mashino, K. Nishida, T. Koga, M. Morita, Y. Kakeji, H. Baba, S. Ohno, and Y. Maehara The association between Akt activation and resistance to hormone therapy in metastatic breast cancer Eur. J. Cancer 42 2006 629 635
19. A. Bellacosa, C.C. Kumar, A.D. Cristofano, and J.R. Testa Activation of AKT kinases in cancer: implications for therapeutic targeting F.V.W. George, K. George, Adv. Cancer Res 2005 Academic Press 29 86
20. L.W. Craig, B.F. Stanley, Y. Melissa, B.T. Mark, and L.E. Mark Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors Curr. Top. Med. Chem. 7 2007 1349 1363
21. Q. Li Recent progress in the discovery of Akt inhibitors as anticancer agents Expert Opin. Ther. Patents 17 2007 1077 1130
22. I. Collins Targeted small-molecule inhibitors of protein kinase B as anticancer agents Anticancer Agents Med. Chem. 9 2009 32 50
23. K. Morrow, L. Du-Cuny, L. Chen, J. Meuillet, A. Mash, G. Powis, and S. Zhang Recent development of anticancer therapeutics targeting Akt Recent Pat. Anticancer Drug Discov. 6 2011 146 159
24. S.K. Pal, K. Reckamp, H. Yu, and R.A. Figlin Akt inhibitors in clinical development for the treatment of cancer Expert Opin. Investig. Drugs 19 2010 1355 1366
25. A. Goel, A.B. Kunnumakkara, and B.B. Aggarwal Curcumin as "curecumin": from kitchen to clinic Biochem. Pharmacol. 75 2008 787 809
26. L.R. Chaudhary, and K.A. Hruska Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells J. Cell. Biochem. 89 2003 1 5
27. J.H. Woo, Y.H. Kim, Y.J. Choi, D.G. Kim, K.S. Lee, J.H. Bae, D.S. Min, J.S. Chang, Y.J. Jeong, and Y.H. Lee Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt Carcinogenesis 24 2003 1199
28. N.M. Weir, K. Selvendiran, V.K. Kutala, L. Tong, S. Vishwanath, M. Rajaram, S. Tridandapani, S. Anant, and P. Kuppusamy Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK Cancer Biol. Ther. 6 2007 178
29. S. Plummer, K. Holloway, M. Manson, R. Munks, A. Kaptein, S. Farrow, and L. Howells Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kB activation via the NIK/IKK signalling complex Oncogene 18 1999 6013 6020
30. S. Singh, and B. Aggarwal Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane) J. Biol. Chem. 270 1995 24995
31. T. Leu, and M. Maa The molecular mechanisms for the antitumorigenic effect of curcumin Curr. Med. Chem. Anticancer Agents 2 2002 357
32. V. Milacic, S. Banerjee, K. Landis-Piwowar, F. Sarkar, A. Majumdar, and Q. Dou Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo Cancer Res. 68 2008 7283
33. S. Aggarwal, H. Ichikawa, Y. Takada, S.K. Sandur, S. Shishodia, and B.B. Aggarwal Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of Iκα kinase and Akt activation Mol. Pharmacol. 69 2006 195
34. D.K. Agrawal, and P.K. Mishra Curcumin and its analogues: potential anticancer agents Med. Res. Rev. 30 2010 818 860
35. B.B. Aggarwal, A. Kumar, and A.C. Bharti Anticancer potential of curcumin: preclinical and clinical studies Anticancer Res. 23 2003 363 398
36. H. Hatcher, R. Planalp, J. Cho, F. Torti, and S. Torti Curcumin: from ancient medicine to current clinical trials Cell. Mol. Life Sci. 65 2008 1631 1652
37. P. Anand, A.B. Kunnumakkara, R.A. Newman, and B.B. Aggarwal Bioavailability of curcumin: problems and promises Mol. Pharm. 4 2007 807 818
38. X. Qiu, Y. Du, B. Lou, Y. Zuo, W. Shao, Y. Huo, J. Huang, Y. Yu, B. Zhou, J. Du, H. Fu, and X. Bu Synthesis and identification of new 4-arylidene curcumin analogues as potential anticancer agents targeting nuclear factor-κB signaling pathway J. Med. Chem. 53 2010 8260 8273
39. V. Basile, E. Ferrari, S. Lazzari, S. Belluti, F. Pignedoli, and C. Imbriano Curcumin derivatives: molecular basis of their anti-cancer activity Biochem. Pharmacol. 78 2009 1305 1315
40. U. Pedersen, P.B. Rasmussen, and S.-O. Lawesson Synthesis of naturally occurring curcuminoids and related compounds Liebigs Ann. Chem. 1985 1985 1557 1569
41. L.V. Rubinstein, R.H. Shoemaker, K.D. Paull, R.M. Simon, S. Tosini, P. Skehan, D.A. Scudiero, A. Monks, and M.R. Boyd Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines J. Natl. Cancer Inst. 82 1990 1113 1117
42. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, and M.R. Boyd New colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst. 82 1990 1107 1112
43. J.J.L. Liao Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors J. Med. Chem. 50 2007 409 424
44. W.M. Weber, L.A. Hunsaker, S.F. Abcouwer, L.M. Deck, and D.L. Vander Jagt Anti-oxidant activities of curcumin and related enones Bioorg. Med. Chem. 13 2005 3811 3820
45. L. Lin, Q. Shi, A.K. Nyarko, K.F. Bastow, C. Wu, C. Su, C.C.Y. Shih, and K. Lee Antitumor agents. 250. design and synthesis of new curcumin analogues as potential anti-prostate cancer agents J. Med. Chem. 49 2006 3963 3972
46. M.J. Frisch, G.W. Trucks, H.B. Schlegel, G.E. Scuseria, M.A. Robb, J.R. Cheeseman, J.A. Montgomery Jr., T. Vreven, K.N. Kudin, J.C. Burant, J.M. Millam, S.S. Iyengar, J. Tomasi, V. Barone, B. Mennucci, M. Cossi, G. Scalmani, N. Rega, G.A. Petersson, H. Nakatsuji, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, M. Klene, X. Li, J.E. Knox, H.P. Hratchian, J.B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R.E. Stratmann, O. Yazyev, A.J. Austin, R. Cammi, C. Pomelli, J.W. Ochterski, P.Y. Ayala, K. Morokuma, G.A. Voth, P. Salvador, J.J. Dannenberg, V.G. Zakrzewski, S. Dapprich, A.D. Daniels, M.C. Strain, O. Farkas, D.K. Malick, A.D. Rabuck, K. Raghavachari, J.B. Foresman, J.V. Ortiz, Q. Cui, A.G. Baboul, S. Clifford, J. Cioslowski, B.B. Stefanov, G. Liu, A. Liashenko, P. Piskorz, I. Komaromi, R.L. Martin, D.J. Fox, T. Keith, M.A. Al-Laham, C.Y. Peng, A. Nanayakkara, M. Challacombe, P.M.W. Gill, B. Johnson, W. Chen, M.W. Wong, C. Gonzalez, and J.A. Pople Gaussian 03, Revision E.01 2004 Gaussian, Inc. Wallingford, CT